GRANULES

Fundamental View- Granules India Ltd is a leading mid-cap pharmaceutical company with strong backward integration, engaged in manufacturing APIs, PFIs, and Finished Dosage Forms. The company holds a dominant position in key products like Paracetamol and Ibuprofen and is steadily expanding its portfolio of high-margin complex generics. With over 60% of its revenue coming from exports, primarily to the US and Europe, Granules has built a strong global presence. Financially, the company reported FY24 revenue of around ₹4,566 crore and net profit of approximately ₹430 crore, supported by stable EBITDA margins of 20% and healthy cash flows. Technical View- As seen in the daily chart, the stock has been trading below its 14 & 55-day EMA since June 24th, indicating short-term weakness. The stock is facing consistent resistance at its 55-day EMA on the daily chart and around its 14-day EMA on the weekly chart. However, one important observation is that the stock is taking strong support near the ₹475.00 level. On June 19th and 20th, the stock made lows around ₹479.00 and witnessed a reversal from there. Even today, the stock traded in a narrow range, opening at ₹492.00, making a high of ₹495.00, a low of ₹487.45, and closing at ₹490.15. On the daily chart, a triangle pattern is forming, and both MACD and RSI are indicating a short-term positive trend. Currently, the stock is trading near ₹490.00, and with a stoploss of ₹475.00, a fresh entry can be considered. If the stock sustains this support and breaks above the resistance zone, it could quickly move towards ₹525.00 levels in the near term. Warning- ***** ***** *****